- Home
- ATAI vs CANG Comparison
ATAI vs CANG Comparison
Compare ATAI & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- CANG
- Stock Information
- Founded
- ATAI 2018
- CANG 2010
- Country
- ATAI Germany
- CANG Hong Kong
- Employees
- ATAI N/A
- CANG N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- CANG Computer Software: Prepackaged Software
- Sector
- ATAI Health Care
- CANG Technology
- Exchange
- ATAI Nasdaq
- CANG Nasdaq
- Market Cap
- ATAI 444.7M
- CANG 509.9M
- IPO Year
- ATAI 2021
- CANG 2018
- Fundamental
- Price
- ATAI $4.66
- CANG $4.66
- Analyst Decision
- ATAI Strong Buy
- CANG Strong Buy
- Analyst Count
- ATAI 3
- CANG 1
- Target Price
- ATAI $13.33
- CANG $8.00
- AVG Volume (30 Days)
- ATAI 5.2M
- CANG 525.4K
- Earning Date
- ATAI 08-14-2025
- CANG 11-03-2025
- Dividend Yield
- ATAI N/A
- CANG N/A
- EPS Growth
- ATAI N/A
- CANG N/A
- EPS
- ATAI N/A
- CANG N/A
- Revenue
- ATAI $2,309,000.00
- CANG $398,195,540.00
- Revenue This Year
- ATAI $661.36
- CANG $469.55
- Revenue Next Year
- ATAI N/A
- CANG $18.83
- P/E Ratio
- ATAI N/A
- CANG N/A
- Revenue Growth
- ATAI 510.85
- CANG 380.74
- 52 Week Low
- ATAI $1.03
- CANG $1.40
- 52 Week High
- ATAI $5.34
- CANG $9.66
- Technical
- Relative Strength Index (RSI)
- ATAI 58.92
- CANG 47.43
- Support Level
- ATAI $4.50
- CANG $4.54
- Resistance Level
- ATAI $4.99
- CANG $5.55
- Average True Range (ATR)
- ATAI 0.35
- CANG 0.32
- MACD
- ATAI -0.04
- CANG -0.02
- Stochastic Oscillator
- ATAI 35.87
- CANG 25.45
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.